Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-011026
Filing Date
2025-05-15
Accepted
2025-05-15 16:42:34
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 557268
2 EX-31.1 ex31-1.htm EX-31.1 8599
3 EX-31.2 ex31-2.htm EX-31.2 8946
4 EX-32.1 ex32-1.htm EX-32.1 8925
5 GRAPHIC form10-q_001.jpg GRAPHIC 7047
  Complete submission text file 0001641172-25-011026.txt   3802656

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20250331.xsd EX-101.SCH 30796
7 XBRL CALCULATION FILE mtnb-20250331_cal.xml EX-101.CAL 47950
8 XBRL DEFINITION FILE mtnb-20250331_def.xml EX-101.DEF 134076
9 XBRL LABEL FILE mtnb-20250331_lab.xml EX-101.LAB 303517
10 XBRL PRESENTATION FILE mtnb-20250331_pre.xml EX-101.PRE 253910
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 410130
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 25954535
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)